Videos

Explore the performance capabilities, technology details, and support resources for the G4 Sequencing Platform and G4X Spatial Sequencer in the videos below.

Play Video

Spatial Product Premiere: The G4X Spatial Sequencer

Spatial biology research faces critical limitations, such as high costs, constrained throughput, and extensive turn-around times. Tune in as we introduce a new era of high-throughput spatial multiomics, the G4X Spatial Sequencer.

Explore G4X

Webinars and Dataset Presentations

G4X Webinar | Performance Workshop & Data Review

In Situ Sequencing: Enabling Spatial Biology at Scale | AGBT 2024 Workshop

The G4 Sequencing Platform Specifications and Capabilities

Advancing Speed, Versatility, and Accuracy in Next Generation Sequencing

Delivering Fast, Flexible Next-Generation
Sequencing

Rapid Targeted Germline and Somatic Variant Detection Using the G4 Sequencing Platform

Previous
Next

Behind the Design: The G4 Sequencing Platform

Intentionally designed to alleviate challenges faced by researchers in the lab today, the G4 Sequencing Platform features advanced engineering and novel chemistry to deliver faster results, with more operational flexibility.

Explore G4
Play Video

G4 Support

G4 Overview

Preparing for a Run

Sample Loading

Disposal of Reagent Cartridge

Handling and Loading Flow Cells

Reagent Cartridges

Custom Primers

Sample Preparation

Water Disposal

Previous
Next
Play Video

We Are Singular

Singular Genomics is ushering in a new era of sequencing and multi-omic discovery. From inception, we have come together to accelerate the advancement of science and medicine.

Drew Spaventa

Drew founded Singular Genomics in 2016 serving as the CEO and Chairman. Drew is a serial entrepreneur and venture investor in the biotech industry and has been involved in the founding of several successful companies. Prior to Singular Genomics, Drew founded Truvian Sciences, a low volume blood testing technology aimed at making routine blood tests easier, less invasive, and more affordable. Drew was also involved in the founding of Aspen Neurosciences where he co-led the seed financing and helped assemble a world-class team to combat Parkinson’s Disease using a patient’s own stem cells. Drew was also a seed investor and held an operating role in Edico Genome which sold to Illumina in 2018.

Drew received an MBA from the Rady School of Management at the University of California, San Diego and a BA in Political Science and International Relations from the University of California, San Diego.

Drew Spaventa

Max Reads Application Note